COMP <GO>
APUS vs NCNA // OPERATING MARGIN
Apimeds Pharmaceuticals US Inc. (NYSE) VS. NuCana plc (NASDAQ) • 15-METRIC TALLY: APUS 2
— NCNA 0
■ METRIC PARITY
LAST: $2.89 (-3.99%) • MKT CAP: $4.6M
operating-margins
—
LAST: $0.98 (-2.96%) • MKT CAP: $4.2M
operating-margins
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (APUS VS. NCNA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | APUS | NCNA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -6.20% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin ACTIVE | — | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 1/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 42.9 | 41.2 | +1.70 | APUS | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $4.6M | $4.2M | $439.7K | APUS | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | APUS REV | NCNA REV | APUS GROSS % | NCNA GROSS % | APUS FCF | NCNA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $33.4M | — | — | — | -$9.0M | — |
| FY 2024 | $3.6M | — | — | — | -$733.5K | — |
| FY 2023 | $2.1M | — | — | — | -$627.8K | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
APUS // BETA —
NCNA // BETA —